Cover Page

Cite item


Previous studies found some associations between immunoglobulin class A antibodies specific to benzo[a]pyrene (IgA-Bp), estradiol (IgA-Es) and progesterone (IgA-Pg) as well as breast cancer (BC) in females and lung cancer (LC) in males. It was suggested that such antibodies affect serum Es and Pg levels.

Our study was aimed at revealing putative features of mutual effects of IgA-Bp, IgA-Es and IgA-Pg on serum Es and Pg level both in healthy and BC females as well as healthy and LC males.

Serum levels of Es and Pg and IgA-Bp, IgA-Es and IgA-Pg were measured by ELISA in 190 nonsmoking healthy and 518 BC females as well as 312 smoking healthy and 196 LC males.

It was found that healthy subjects vs cancer patients prominently differed by assessing individual Pg/Es ratios: healthy vs BC females had it set at 6.6 vs 2.9 (p < 0.0001), respectively, whereas in healthy vs LC males it was at 5.2 vs 10.1 (p < 0.0001), respectively.

Individual Pg/Es ratio paralleled in healthy females with high vs low IgA-Bp/IgA-Pg > 1.5 and IgA-Es/IgA-Pg > 1.5 ratios (3.5 vs 9.7, p < 0.0001). No T such associations were observed in BC patients. In addition, the lowest individual Pg/Es ratio in healthy males was found together with IgA-Es/ IgA-Pg > 1.5 ratios accompanied with IgA-Bp/IgA-Pg ≤ 1.5 (2.9) and peaked in case of concurrently low IgA-Bp/IgA-Pg ≤ 1.5 and IgA-Es/IgA-Pg ≤ 1.5 (5.2, p = 0.005) or high IgA-Bp/IgA-Pg > 1.5 and IgA-Es/IgA-Pg > 1.5 (6.5, p = 0.002). In contrast, the lowest Pg/Es ratio (7.4) was revealed in LC patients simultaneously bearing high IgA-Bp/IgA-Pg > 1.5 and low IgA-Es/IgA-Pg ≤ 1.5 ratios compared to simultaneously low ratios (11.3, p = 0.002).

In conclusion, individual Pg/Es ratios depended on individual IgA-Bp/IgA-Pg and IgA-Es/IgA-Pg ratios. A cooperative influence of serum antibodies specific to environmental chemical carcinogens and endogenous steroids on hormone balance was featured both in healthy subjects as well as BC females and LC males.

The data obtained may be useful while developing new strategies to cancer prevention: by using selective modulators of estrogen receptors and aromatase inhibitors as well as for development of anticancer vaccines.

About the authors

A. N. Glushkov

Institute of Human Ecology, Federal Research Center of Coal and Coal Chemistry, Siberian Branch, Russian Academy of Sciences

Glushkov A.N., PhD, MD (Medicine), Professor, Chief Research Associate, Immunogenetics Laboratory Russian Federation

E. G. Polenok

Institute of Human Ecology, Federal Research Center of Coal and Coal Chemistry, Siberian Branch, Russian Academy of Sciences

Polenok E.G., PhD (Pharmacy), Leading Research Associate, Immunochemistry Laboratory Russian Federation

S. A. Mun

Institute of Human Ecology, Federal Research Center of Coal and Coal Chemistry, Siberian Branch, Russian Academy of Sciences

Author for correspondence.

Mun Stella A., PhD (Medicine), Senior Research Associate, Immunogenetics Laboratory

650065, Kemerovo, Leningradsky ave., 10. Phone: 7 (3842) 57-50-79

Russian Federation

L. A. Gordeeva

Institute of Human Ecology, Federal Research Center of Coal and Coal Chemistry, Siberian Branch, Russian Academy of Sciences

Gordeeva L.A., PhD (Biology), Leading Research Associate, Immunogenetics Laboratory Russian Federation

M. V. Kostyanko

Institute of Fundamental Sciences, Kemerovo State University

Kostyanko M.V., Leading Engineer, Organic Chemistry Department Russian Federation

G. I. Kolpinsky

Kemerovo State Medical University;
Kemerovo Clinical Diagnostic Center

Kolpinsky G.I., PhD, MD (Medicine), Professor, Department of Radiology and Radiotherapy with the Course of Oncology Russian Federation

V. A. Lutsenko

Regional Clinical Oncology Dispensary

Lutsenko V.A., PhD (Medicine), Chief Physician Russian Federation

A V. Antonov

Regional Clinical Oncology Dispensary

Antonov A.V., Head, Mammology Department Russian Federation

V. A. Titov

Regional Clinical Oncology Dispensary

Titov V.A., Oncologist Russian Federation

I. A. Vafin

Regional Center of Blood

Vafin I.A., Chief Physician Russian Federation


  1. Глушков А.Н., Поленок Е.Г., Гордеева Л.А., Мун С.А., Костянко М.В., Антонов А.В., Титов В.А., Вержбицкая Н.Е., Вафин И.А. Иммунологический дисбаланс при раке молочной железы и раке легкого у женщин в постменопаузе // Медицинская иммунология, 2018. Т. 20, № 6. С. 927-934. doi: 10.15789/1563-0625-2018-6-927-934.
  2. Глушков А.Н., Поленок Е.Г., Костянко М.В., Рогозин А.И., Антонов А.В., Вержбицкая Н.Е. Совместное влияние антител к бензо[a]пирену, эстрадиолу и прогестерону на содержание женских половых гормонов в сыворотке крови у больных раком молочной железы // Российский иммунологический журнал, 2018. Т. 12, № 21. С. 40-45.
  3. Глушков А.Н., Поленок Е.Г., Костянко М.В., Антонов А.В., Вержбицкая Н.Е., Вафин И.А., Рагожина С.Е. Антитела и анти-антитела к стероидным гормонам и риск рака молочной железы // Медицинская иммунология, 2017, Т. 19, № 5. C. 577-584. doi: 10.15789/1563-0625-2017-5-577-58.
  4. Глушков А.Н., Поленок Е.Г., Мун С.А., Гордеева Л.А., Костянко М.В., Антонов А.В., Вержбицкая Н.Е., Вафин И.А. Индивидуальный иммунологический фенотип и риск рака молочной железы у женщин в постменопаузе // Российский иммунологический журнал, 2019, Т. 13, № 1. С. 44-52.
  5. Cavalieri E.L., Rogan E.G. Depurinating estrogen-DNA adducts, generators of cancer initiation: their minimization leads to cancer prevention. Clin. Transl. Med., 2016, Vol. 5, no. 1, 12. doi: 10.1186/s40169-016-0088-3.
  6. Ceppi M., Munnia A., Cellai F., Bruzzone M., Peluso MEM. Linking the generation of DNA adducts to lung cancer. Toxicology, 2017, Vol. 390, pp. 160-166.
  7. Chen Z., Zhang Y., Yang J., Jin M., Wang X.W., Shen Z.Q., Qiu Z., Zhao G., Wang J., Li J.W. Estrogen promotes benzo[a]pyrene-induced lung carcinogenesis through oxidative stress damage and cytochrome c-mediated caspase-3 activation pathway in female mice. Cancer Lett., 2011, Vol. 308, no. 1, pp. 14-22.
  8. DeBuck S.S., Muller C.P. Immunopropylactic approaches against chemical carcinogenesis. Vaccine 2005, Vol. 23, no. 17-18, pp. 2403-2406.
  9. Elsaesser F. Effects of active immunization against oestradiol-17 beta, testosterone or progesterone on receptivity in the female rabbit and evaluation of specificity. J. Reprod. Fertil., 1980, Vol. 58, no. 1, pp. 213-218.
  10. French L.R., Spennetta B. Effects of antibodies to progesterone on reproduction of ewes. Theriogenology, 1981, Vol. 16, no. 4, pp. 407-418.
  11. Grova N., Prodhomme E.J., Schellenberger M.T., Farinelle S., Muller C.P. Modulation of carcinogen bioavailability by immunisation with benzo[a]pyrene – conjugate vaccines. Vaccine, 2009, Vol. 27, no. 31, pp. 4142-4151.
  12. Kang S.C., Lee B.M. Effect of estrogen receptor (ER) on benzo[a]pyrene-DNA adduct formation in human breast cancer cells. J. Toxicol. Environ. Health A, 2005, Vol. 68, no. 21, pp. 1833-1840.
  13. Lin S., Lin C.J., Hsieh D.P., Li L.A. ERα phenotype, estrogen level, and benzo[a]pyrene exposure modulate tumor growth and metabolism of lung adenocarcinoma cells. Lung Cancer, 2012, Vol. 75, no. 3, pp. 285-292.
  14. Mohammed H., Russell I.A., Stark R., Rueda O.M., Hickey T.E., Tarulli G.A., Serandour A.A., Birrell S.N., Bruna A., Saadi A., Menon S., Hadfield J., Pugh M., Raj G.V., Brown G.D., D’Santos C., Robinson J.L., Silva G., Launchbury R., Perou C.M., Stingl J., Caldas C., Tilley W.D., Carroll J.S. Progesterone receptor modulates ERα action in breast cancer. Nature, 2015, Vol. 523, no. 7560, pp. 313-317.
  15. Rosenberg M., Amir D., Folman Y. The effect of active immunization against progesterone on plasma concentrations of total and free progesterone, estradiol-17beta and LH in the cyclic ewe. Theriogenology, 1987, Vol. 28, no. 4, pp. 417-426.
  16. Rundle A., Tang D., Hibshoosh H., Estabrook A., Schnabel F., Cao W., Grumet S., Perera F.P. The relationship between genetic damage from polycyclic aromatic hydrocarbons in breast tissue and breast cancer. Carcinogenesis, 2000, Vol. 21, no. 7, pp. 1281-1289.
  17. Schellenberger M.T., Farinelle S., Willième S., Muller C.P. Evaluation of adjuvants for a candidate conjugate vaccine against benzo[a]pyrene. Hum. Vaccin., 2011, Vol. 7, no. 1, pp. 166-173.
  18. Sestak I. Preventative therapies for healthy women at high risk of breast cancer. Cancer Manag. Res., 2014, Vol. 6, pp. 423-430.
  19. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2017. CA Cancer J. Clin., 2017, Vol. 67, no. 1, pp. 7-30.
  20. Ustinov V.A., Matveeva V.A., Kostyanko M.V., Glushkov A.N. Antibodies against benzo[a]pyrene in immunized mouse and lung cancer patients. Exp. Oncol., 2013, Vol. 35, no. 3, pp. 207-210.
  21. Vogel V.G. Role of hormones in cancer prevention. Am. Soc. Clin. Oncol. Educ. Book, 2014, pp. 34-40.

Copyright (c) 2020 Glushkov A.N., Polenok E.G., Mun S.A., Gordeeva L.A., Kostyanko M.V., Kolpinsky G.I., Lutsenko V.A., Antonov A.V., Titov V.A., Vafin I.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № 77 - 11525 от 04.01.2002.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies